Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Rhino-Orbital-Cerebral Mucormycosis after Allogeneic Hematopoietic Stem Cell Transplantation and Isavuconazole Therapeutic Drug Monitoring during Intestinal Graft versus Host Disease.

Andreani G, Fadda G, Gned D, Dragani M, Cavallo G, Monticone V, Morotti A, De Gobbi M, Guerrasio A, Barbui AM, D'Avolio A, Cilloni D.

Mediterr J Hematol Infect Dis. 2019 Nov 1;11(1):e2019061. doi: 10.4084/MJHID.2019.061. eCollection 2019.

2.

Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial.

Bruna R, Benedetti F, Boccomini C, Patti C, Barbui AM, Pulsoni A, Musso M, Liberati AM, Gini G, Castellino C, Rossini F, Ciceri F, Rota-Scalabrini D, Stelitano C, Di Raimondo F, Tucci A, Devizzi L, Zoli V, Zallio F, Narni F, Dondi A, Parvis G, Semenzato G, Lanza F, Perrone T, Angrilli F, Billio A, Gueli A, Mantoan B, Rambaldi A, Gianni AM, Corradini P, Passera R, Ladetto M, Tarella C.

Haematologica. 2019 Nov;104(11):2241-2248. doi: 10.3324/haematol.2018.209932. Epub 2019 Apr 11.

3.

Cocirculation of Hajj and non-Hajj strains among serogroup W meningococci in Italy, 2000 to 2016.

Fazio C, Neri A, Vacca P, Ciammaruconi A, Arghittu M, Barbui AM, Vocale C, Bernaschi P, Isola P, Galanti IA, Mencacci A, De Nittis R, Chironna M, Giammanco A, Pagani E, Bisbano A, Stefanelli P.

Euro Surveill. 2019 Jan;24(4). doi: 10.2807/1560-7917.ES.2019.24.4.1800183.

4.

Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.

Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Dürig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE.

J Clin Oncol. 2018 Aug 10;36(23):2395-2404. doi: 10.1200/JCO.2017.76.8960. Epub 2018 Jun 1.

PMID:
29856692
5.

A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy.

Trnĕný M, Verhoef G, Dyer MJ, Ben Yehuda D, Patti C, Canales M, Lopez A, Awan FT, Montgomery PG, Janikova A, Barbui AM, Sulek K, Terol MJ, Radford J, Guidetti A, Di Nicola M, Siraudin L, Hatteville L, Schwab S, Oprea C, Gianni AM.

Haematologica. 2018 Aug;103(8):1351-1358. doi: 10.3324/haematol.2017.168401. Epub 2018 May 10.

6.

Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy.

Gritti G, Gianatti A, Petronzelli F, De Santis R, Pavoni C, Rossi RL, Cattaneo L, Spagnoli LG, Ferrari S, Rossi A, Barbui AM, Rambaldi A.

Oncotarget. 2018 Jan 3;9(11):9766-9775. doi: 10.18632/oncotarget.23919. eCollection 2018 Feb 9. Erratum in: Oncotarget. 2018 Mar 30;9(24):17256.

7.

Molecular Characterization of Penicillinase-Producing Neisseria gonorrhoeae Isolated in Two Time Periods, 2003-2004 and 2014-2015, in Italy.

Stefanelli P, Carannante A, Bonanno CL, Cusini M, Ghisetti V, Mencacci A, Barbui AM, Prignano G, Vocale C, Vacca P.

Microb Drug Resist. 2018 Jun;24(5):621-626. doi: 10.1089/mdr.2017.0218. Epub 2018 Jan 2.

PMID:
29293395
8.

Time trend analysis (2009-2016) of antimicrobial susceptibility in Neisseria gonorrhoeae isolated in Italy following the introduction of the combined antimicrobial therapy.

Stefanelli P, Vescio MF, Landini MP, Dal Conte I, Matteelli A, Cristaudo A, Gaino M, Cusini M, Barbui AM, Mencacci A, De Nittis R, Ghisetti V, Stroppiana E, Carannante A; Neisseria gonorrhoeae antimicrobials resistant Study Group.

PLoS One. 2017 Dec 14;12(12):e0189484. doi: 10.1371/journal.pone.0189484. eCollection 2017.

9.

Subgingival Microbiota in White Patients With Desquamative Gingivitis: A Cross-Sectional Study.

Arduino PG, Romano F, Sasia D, Broccoletti R, Ricceri F, Barbui AM, Brossa S, Cipriani R, Cricenti L, Cabras M, Aimetti M.

J Periodontol. 2017 Jul;88(7):643-650. doi: 10.1902/jop.2017.160745. Epub 2017 Mar 17.

PMID:
28304209
10.

Chronic amastigote-negative cutaneous leishmaniasis: A clinical, histopathologic and molecular study of 27 cases with emphasis on atypical and pseudolymphomatous presentations.

Tomasini C, Moneghini L, Barbui AM.

J Cutan Pathol. 2017 Jun;44(6):530-537. doi: 10.1111/cup.12927. Epub 2017 Apr 10.

PMID:
28294400
11.

Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas.

Cortelazzo S, Tarella C, Gianni AM, Ladetto M, Barbui AM, Rossi A, Gritti G, Corradini P, Di Nicola M, Patti C, Mulé A, Zanni M, Zoli V, Billio A, Piccin A, Negri G, Castellino C, Di Raimondo F, Ferreri AJ, Benedetti F, La Nasa G, Gini G, Trentin L, Frezzato M, Flenghi L, Falorio S, Chilosi M, Bruna R, Tabanelli V, Pileri S, Masciulli A, Delaini F, Boschini C, Rambaldi A.

J Clin Oncol. 2016 Nov 20;34(33):4015-4022. doi: 10.1200/JCO.2016.67.2980. Epub 2016 Oct 31.

12.

Rapid Identification of Microorganisms from Positive Blood Culture by MALDI-TOF MS After Short-Term Incubation on Solid Medium.

Curtoni A, Cipriani R, Marra ES, Barbui AM, Cavallo R, Costa C.

Curr Microbiol. 2017 Jan;74(1):97-102. doi: 10.1007/s00284-016-1161-2. Epub 2016 Nov 17.

13.

Caulobacter spp: A Rare Pathogen Responsible for Paucisintomatic Persisitant Meningitis in a Glioblastoma Patient.

Penner F, Brossa S, Barbui AM, Ducati A, Cavallo R, Zenga F.

World Neurosurg. 2016 Dec;96:611.e11-611.e13. doi: 10.1016/j.wneu.2016.09.020. Epub 2016 Sep 17.

PMID:
27650802
14.

Erratum to: MagicplexTM Sepsis Real-Time test to improve bloodstream infection diagnostics in children.

Denina M, Scolfaro C, Colombo S, Calitri C, Garazzino S, Barbui AM, Brossa S; Regina Margherita Children’s Hospital Bloodstream Infections Study Group participants, Tovo PA.

Eur J Pediatr. 2016 Sep;175(9):1253. doi: 10.1007/s00431-016-2753-3. No abstract available.

PMID:
27457371
15.

Louseborne Relapsing Fever among East African Refugees, Italy, 2015.

Lucchini A, Lipani F, Costa C, Scarvaglieri M, Balbiano R, Carosella S, Calcagno A, Audagnotto S, Barbui AM, Brossa S, Ghisetti V, Dal Conte I, Caramello P, Di Perri G.

Emerg Infect Dis. 2016 Feb;22(2):298-301. doi: 10.3201/eid2202.151768.

16.

Persistent occurrence of serogroup Y/sequence type (ST)-23 complex invasive meningococcal disease among patients aged five to 14 years, Italy, 2007 to 2013.

Fazio C, Neri A, Renna G, Vacca P, Antonetti R, Barbui AM, Daprai L, Lanzafame P, Rossi L, Santino I, Tascini C, Vocale C, Stefanelli P.

Euro Surveill. 2015;20(45). doi: 10.2807/1560-7917.ES.2015.20.45.30061.

17.

Primary treatment response rather than front line stem cell transplantation is crucial for long term outcome of peripheral T-cell lymphomas.

Gritti G, Boschini C, Rossi A, Delaini F, Grassi A, Algarotti A, Micò C, Trezzi R, Gianatti A, Barbui AM, Rambaldi A.

PLoS One. 2015 Mar 27;10(3):e0121822. doi: 10.1371/journal.pone.0121822. eCollection 2015.

18.

Rate of primary refractory disease in B and T-cell non-Hodgkin's lymphoma: correlation with long-term survival.

Tarella C, Gueli A, Delaini F, Rossi A, Barbui AM, Gritti G, Boschini C, Caracciolo D, Bruna R, Ruella M, Gottardi D, Passera R, Rambaldi A.

PLoS One. 2014 Sep 25;9(9):e106745. doi: 10.1371/journal.pone.0106745. eCollection 2014.

19.

Prevention of invasive fungal infections in patients with acute myeloid leukaemia: results of a single centre retrospective observational study with the use of posaconazole versus conventional mould-active azoles.

Dellacasa CM, Busca A, Audisio E, Marmont F, Barbui AM, Falda M, De Rosa FG, Frairia C, Allione B, D'Ardia S, Aydin S, Pecoraro C, Manetta S, Vitolo U.

J Chemother. 2014 Oct;26(5):315-20. doi: 10.1179/1973947813Y.0000000142. Epub 2013 Dec 6. No abstract available.

PMID:
24075616
20.

The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy.

Rambaldi A, Boschini C, Gritti G, Delaini F, Oldani E, Rossi A, Barbui AM, Caracciolo D, Ladetto M, Gueli A, De Crescenzo A, Passera R, Devizzi L, Patti C, Gianni AM, Tarella C.

Am J Hematol. 2013 Dec;88(12):1062-7. doi: 10.1002/ajh.23566. Epub 2013 Sep 30.

21.

Moxifloxacin for the treatment of pulmonary tuberculosis in children: a single center experience.

Garazzino S, Scolfaro C, Raffaldi I, Barbui AM, Luccoli L, Tovo PA.

Pediatr Pulmonol. 2014 Apr;49(4):372-6. doi: 10.1002/ppul.22755. Epub 2013 Feb 8.

22.

The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells.

Golay J, Cuppini L, Leoni F, Micò C, Barbui V, Domenghini M, Lombardi L, Neri A, Barbui AM, Salvi A, Pozzi P, Porro G, Pagani P, Fossati G, Mascagni P, Introna M, Rambaldi A.

Leukemia. 2007 Sep;21(9):1892-900. Epub 2007 Jul 19.

PMID:
17637810
23.

Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study.

Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, Dander E, Gaipa G, D'Amico G, Biagi E, Parma M, Pogliani EM, Spinelli O, Baronciani D, Grassi A, Golay J, Barbui T, Biondi A, Rambaldi A.

Haematologica. 2007 Jul;92(7):952-9.

24.

Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.

Barbui AM, Borleri G, Conti E, Ciocca A, Salvi A, Micò C, Introna M, Rambaldi A.

Exp Hematol. 2006 Apr;34(4):475-85.

PMID:
16569594
25.

Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma.

Galli M, Nicolucci A, Valentini M, Belfiglio M, Delaini F, Crippa C, Barbui AM, Giussani U, Rambaldi A, Barbui T.

Haematologica. 2005 Dec;90(12):1643-9.

26.

Correlation between fatigue and hemoglobin level in multiple myeloma patients: results of a cross-sectional study.

Palumbo A, Petrucci MT, Lauta VM, Musto P, Caravita T, Barbui AM, Nunzi M, Boccadoro M; Italian Multiple Myeloma Study Group.

Haematologica. 2005 Jun;90(6):858-60.

27.

Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo.

Golay J, Di Gaetano N, Amico D, Cittera E, Barbui AM, Giavazzi R, Biondi A, Rambaldi A, Introna M.

Br J Haematol. 2005 Feb;128(3):310-7.

PMID:
15667532
28.

Minor histocompatibility antigen-specific T cells with multiple distinct specificities can be isolated by direct cloning of IFNgamma-secreting T cells from patients with relapsed leukemia responding to donor lymphocyte infusion.

Kloosterboer FM, van Luxemburg-Heijs SA, van Soest RA, van Egmond HM, Barbui AM, Strijbosch MP, Willemze R, Falkenburg JH.

Leukemia. 2005 Jan;19(1):83-90.

PMID:
15526024
29.

Innovative cell-based therapies in onco-hematology: what are the clinical facts ?

Introna M, Barbui AM, Golay J, Rambaldi A.

Haematologica. 2004 Oct;89(10):1253-60. Review.

30.

Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells.

Kloosterboer FM, van Luxemburg-Heijs SA, van Soest RA, Barbui AM, van Egmond HM, Strijbosch MP, Kester MG, Marijt WA, Goulmy E, Willemze R, Falkenburg JH.

Leukemia. 2004 Apr;18(4):798-808.

PMID:
14973499
31.

Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study.

Bianco E, Marcucci F, Mele A, Musto P, Cotichini R, Sanpaolo MG, Iannitto E, De Renzo A, Martino B, Specchia G, Montanaro M, Barbui AM, Nieddu R, Pagano L, Rapicetta M, Franceschi S, Mandelli F, Pulsoni A; Italian Multi-Center case-control study.

Haematologica. 2004 Jan;89(1):70-6.

32.

Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3.

Amico D, Barbui AM, Erba E, Rambaldi A, Introna M, Golay J.

Blood. 2003 Jun 1;101(11):4589-97. Epub 2003 Feb 6.

PMID:
12576328
33.

Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma.

Barbui AM, Galli M, Dotti G, Belli N, Borleri G, Gritti G, Bellavita P, Viero P, Comotti B, Barbui T, Rambaldi A.

Br J Haematol. 2002 Jan;116(1):202-10.

PMID:
11841418
34.

Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis.

Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, Gentilcore E, Piantino P, Barbui AM, David E, Negro F, Rizzetto M.

J Hepatol. 2001 Jun;34(6):903-10.

PMID:
11451175
35.

Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies.

Introna M, Barbui AM, Bambacioni F, Casati C, Gaipa G, Borleri G, Bernasconi S, Barbui T, Golay J, Biondi A, Rambaldi A.

Hum Gene Ther. 2000 Mar 1;11(4):611-20.

PMID:
10724039
36.

Rapid retroviral infection of human haemopoietic cells of different lineages: efficient transfer in fresh T cells.

Introna M, Barbui AM, Golay J, Bambacioni F, Schirò R, Bernasconi S, Breviario F, Erba E, Borleri G, Barbui T, Biondi A, Rambaldi A.

Br J Haematol. 1998 Nov;103(2):449-61.

PMID:
9827919

Supplemental Content

Loading ...
Support Center